要闻！《敦煌英雄》定档12月22日：大唐历史登大银幕 传承千年文化 弘扬民族精神

《敦煌英雄》定档12月22日：大唐历史登大银幕 传承千年文化 弘扬民族精神

北京 - 由曹盾执导、马伯庸编剧、张苗担任出品人兼总制片人的古装动作传奇电影《敦煌英雄》今日宣布定档12月22日，并发布定档海报和预告片。影片以真实历史为背景，讲述了安史之乱后，敦煌守将张议潮率领“归义军”浴血奋战，最终收复敦煌的故事。

实力派演员同台飙戏 演绎敦煌传奇

《敦煌英雄》集结了章宇、窦骁、吕凉、张艺凡、雷佳音、朱亚文、李光洁等实力派演员。章宇饰演的男主角张议潮，是一位胸怀家国、骁勇善战的将领。窦骁饰演的曹光宗，是张议潮的副手，两人并肩作战，共赴国难。吕凉饰演的反派角色任恐热，阴险狡诈，野心勃勃。张艺凡饰演的张月牙，是张议潮的女儿，巾帼不让须眉，立志报国。雷佳音、朱亚文、李光洁等演员也将在片中饰演重要角色，为影片增添了诸多亮点。

恢弘制作 再现盛唐风貌

《敦煌英雄》在制作上精益求精，力求打造出一部视觉上震撼、故事上动人的作品。影片的拍摄辗转敦煌、甘肃等地，美术置景、服装道具等方面都经过了精心的考证和设计，最大程度地还原了盛唐时期的历史风貌。影片的动作场面也十分精彩，拳拳到肉，极具观赏性。

传承文化 弘扬精神

敦煌是中华文明的重要瑰宝，而“归义军”的故事更是鲜为人知。《敦煌英雄》以电影的形式将这段历史搬上银幕，不仅具有重要的文化意义，也具有强烈的现实意义。影片歌颂了张议潮和“归义军”的爱国主义精神和英雄气概，激励着人们不忘历史、传承文化、弘扬民族精神。

《敦煌英雄》将于12月22日全国上映，让我们一起期待这部电影，感受大唐历史的磅礴魅力，重温“归义军”的英雄事迹！

以下为影片主要信息：

• 片名：《敦煌英雄》
• 导演：曹盾
• 编剧：马伯庸
• 主演：章宇、窦骁、吕凉、张艺凡、雷佳音、朱亚文、李光洁
• 上映日期：2023年12月22日

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.